KR100262371B1 - 퀴스퀄레이트 수용체에 대한 친화성이 있는 퀴녹살린 유도체 - Google Patents

퀴스퀄레이트 수용체에 대한 친화성이 있는 퀴녹살린 유도체 Download PDF

Info

Publication number
KR100262371B1
KR100262371B1 KR1019930701948A KR930701948A KR100262371B1 KR 100262371 B1 KR100262371 B1 KR 100262371B1 KR 1019930701948 A KR1019930701948 A KR 1019930701948A KR 930701948 A KR930701948 A KR 930701948A KR 100262371 B1 KR100262371 B1 KR 100262371B1
Authority
KR
South Korea
Prior art keywords
acid
dioxo
tetrahydroquinoxalin
alkyl
nitro
Prior art date
Application number
KR1019930701948A
Other languages
English (en)
Korean (ko)
Other versions
KR930703271A (ko
Inventor
안드레아스 후트
랄프 쉬미헨
일제 베쯔
잉그리트 슈만
레호스라브 투르스키
페터 안드레아스 뢰쉬만
다비드 노르만 스테펜즈
디터 자이델만
마르틴 크뤼거
디터 라흐쯔
페터 횔세르
Original Assignee
에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만
쉐링 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4135871A external-priority patent/DE4135871A1/de
Application filed by 에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만, 쉐링 악티엔게젤샤프트 filed Critical 에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만
Publication of KR930703271A publication Critical patent/KR930703271A/ko
Application granted granted Critical
Publication of KR100262371B1 publication Critical patent/KR100262371B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/650952Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019930701948A 1991-10-26 1992-10-25 퀴스퀄레이트 수용체에 대한 친화성이 있는 퀴녹살린 유도체 KR100262371B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DEP4135871.6 1991-10-26
DE4135871A DE4135871A1 (de) 1991-10-26 1991-10-26 Chinoxalinderivate, deren herstellung und verwendung in arzneimitteln
DEP4224200.2 1992-07-17
DE4224200 1992-07-17
PCT/DE1992/000895 WO1993008173A1 (fr) 1991-10-26 1992-10-25 Derives de quinoxaline ayant une affinite pour les recepteurs de quisqualate

Publications (2)

Publication Number Publication Date
KR930703271A KR930703271A (ko) 1993-11-29
KR100262371B1 true KR100262371B1 (ko) 2000-08-01

Family

ID=25908683

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930701948A KR100262371B1 (ko) 1991-10-26 1992-10-25 퀴스퀄레이트 수용체에 대한 친화성이 있는 퀴녹살린 유도체

Country Status (17)

Country Link
EP (1) EP0565683A1 (fr)
JP (1) JP3258008B2 (fr)
KR (1) KR100262371B1 (fr)
CN (1) CN1038840C (fr)
AU (1) AU664212B2 (fr)
CA (1) CA2099270A1 (fr)
CZ (1) CZ286351B6 (fr)
FI (1) FI932959A0 (fr)
HU (1) HUT64756A (fr)
IL (1) IL103538A (fr)
NO (1) NO304693B1 (fr)
NZ (1) NZ244896A (fr)
PL (1) PL171125B1 (fr)
PT (1) PT101004B (fr)
RU (1) RU2117663C1 (fr)
SK (1) SK281518B6 (fr)
WO (1) WO1993008173A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162491D0 (da) * 1991-09-20 1991-09-20 Novo Nordisk As Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
ATE404201T1 (de) * 1992-06-22 2008-08-15 Univ California Glycinrezeptorantagonisten und ihre verwendung
DE4314592A1 (de) * 1993-04-28 1994-11-03 Schering Ag Benzo(f)chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
DE4428152A1 (de) * 1994-06-22 1996-01-04 Basf Ag Neue Amido-chinoxalindione, ihrer Herstellung und Verwendung
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
HU223945B1 (hu) * 1994-09-27 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. 1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE4439493A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
DE19521058A1 (de) * 1995-06-09 1996-12-12 Basf Ag Verfahren zur Herstellung von Aromaten enthaltenden Polyetherpolyolen
DE19545251A1 (de) * 1995-11-24 1997-05-28 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
TW448171B (en) * 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
DE19624808A1 (de) 1996-06-21 1998-01-02 Basf Ag Pyrrolylchinoxalindione, ihre Herstellung und Verwendung
DE19728326A1 (de) * 1997-06-27 1999-01-07 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
US6015800A (en) * 1997-09-03 2000-01-18 Warner-Lambert Company Substituted quinoxaline-2-ones as glutamate receptor antagonists
EP0900567A3 (fr) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-ones antagonistes d'AMPA pour le traitement des dyscinésies associées à la thérapie aux agonistes de la dopamine
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
FR2769309B1 (fr) 1997-10-08 2001-06-15 Oreal Composition de teinture d'oxydation des fibres keratiniques comprenant un derive d'aminoacide en tant que base d'oxydation et nouveaux derives d'aminoacides
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013878A1 (fr) * 1990-03-16 1991-09-19 Novo Nordisk A/S Composes de quinoxaline, preparation et utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0118982A1 (fr) * 1983-02-01 1984-09-19 Sumitomo Chemical Company, Limited Composés organo-phosphorés de la quinoxalinone, leur production et utilisation
NO179551C (no) * 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991013878A1 (fr) * 1990-03-16 1991-09-19 Novo Nordisk A/S Composes de quinoxaline, preparation et utilisation

Also Published As

Publication number Publication date
FI932959A (fi) 1993-06-24
NZ244896A (en) 1995-07-26
CZ138793A3 (en) 1994-01-19
NO304693B1 (no) 1999-02-01
AU2889492A (en) 1993-05-21
SK281518B6 (sk) 2001-04-09
SK72793A3 (en) 1993-10-06
CZ286351B6 (cs) 2000-03-15
EP0565683A1 (fr) 1993-10-20
PL299929A1 (en) 1994-04-05
HUT64756A (en) 1994-02-28
CN1072929A (zh) 1993-06-09
IL103538A0 (en) 1993-03-15
CA2099270A1 (fr) 1993-04-27
AU664212B2 (en) 1995-11-09
WO1993008173A1 (fr) 1993-04-29
NO932344L (no) 1993-06-25
IL103538A (en) 2001-07-24
JPH06503583A (ja) 1994-04-21
NO932344D0 (no) 1993-06-25
KR930703271A (ko) 1993-11-29
PT101004B (pt) 1999-10-29
PL171125B1 (pl) 1997-03-28
JP3258008B2 (ja) 2002-02-18
FI932959A0 (fi) 1993-06-24
RU2117663C1 (ru) 1998-08-20
HU9301877D0 (en) 1993-09-28
CN1038840C (zh) 1998-06-24
PT101004A (pt) 1994-01-31

Similar Documents

Publication Publication Date Title
KR100262371B1 (ko) 퀴스퀄레이트 수용체에 대한 친화성이 있는 퀴녹살린 유도체
US5750525A (en) Quinoxalinedione derivatives, their production and use in pharmaceutical agents
US6143733A (en) Quinoxalinedione derivatives, their production and use in pharmaceutical agents
US6288065B1 (en) Quinoxaline-carboxylic acid derivatives
US6136805A (en) Quinoxaline dione derivatives, their production and their use in medicaments
AU720083B2 (en) New quinoxalindione derivatives, their production and use in pharmaceutical agents
US5710138A (en) Benzo f!quinoxalinedione derivatives, their production and use in pharmaceutical agents
WO1996008492A1 (fr) DERIVES DE LA [1,2,4]TRIAZOLO[4,3-a]QUINOXALINONE, LEUR PREPARATION ET UTILISATION
US5750526A (en) Pyrido 1,2,3-DE!quinoxaline derivatives, process for their production and their use in pharmaceutical agents
JPH10506620A (ja) 〔1,2,4〕トリアゾロ〔4,3−a〕キノキサリノン誘導体、それらの調製方法及び使用
US6596709B1 (en) 6-sulphanoyl-3-quinolylphosphonic acid compounds

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee